Drug name - Jevtana Kit

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7241907 SANOFI AVENTIS US Acetone solvate of dimethoxy docetaxel and its process of preparation
Dec, 2025

(3 years from now)

CN100429207C SANOFI AVENTIS US Dimethoxy Docetaxel Acetone Compound And Preparation Method Thereof
Sep, 2024

(1 year, 11 months from now)

CN1849311A SANOFI AVENTIS US Dimethoxy Docetaxel Acetone Compound And Preparation Method Thereof
Sep, 2024

(1 year, 11 months from now)

IN253669B SANOFI AVENTIS US A Process For The Preparation Of Acetone Solvate Of Dimethoxy Docetaxel
Sep, 2024

(1 year, 11 months from now)

IN200600944P4 SANOFI AVENTIS US Dimethoxy Docetaxel Acetone Solvate Et Method For The Preparation Thereof
Sep, 2024

(1 year, 11 months from now)

EP1667986A1 SANOFI AVENTIS US Dimethoxy Docetaxel Acetone Solvate Et Method For The Preparation Thereof
Mar, 2026

(3 years from now)

EP1667986B1 SANOFI AVENTIS US Dimethoxy Docetaxel Acetone Solvate Et Method For The Preparation Thereof
Mar, 2026

(3 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7241907

(Pediatric)

SANOFI AVENTIS US Acetone solvate of dimethoxy docetaxel and its process of preparation Jun, 2026

(3 years from now)

US10583110 SANOFI AVENTIS US Antitumoral use of cabazitaxel Oct, 2030

(8 years from now)

US10716777 SANOFI AVENTIS US Antitumoral use of cabazitaxel Oct, 2030

(8 years from now)

US8927592 SANOFI AVENTIS US Antitumoral use of cabazitaxel Oct, 2030

(8 years from now)

US8927592

(Pediatric)

SANOFI AVENTIS US Antitumoral use of cabazitaxel Apr, 2031

(8 years from now)

Drugs and Companies using CABAZITAXEL ingredient

Treatment: Increasing survival in metastatic castration-resistant prostate cancer patients previously treated with docetaxel by administering as a 3 week cycle cabazitaxel after 5 mg dexchlorpheniramine, 8 mg dexamethasone, and an h2-agonist; Increasing survival in metastatic castration-resistant prostate cancer patients previously treated with docetaxel by administering 20 to 25 mg/m2 cabazitaxel after a premedication regimen that includes an h2-antagonist; Increasing survival in mcrpc patients previously treated with docetaxel by administering cabazitaxel in combination with prednisone or prednisolone after a premedication regimen that includes an antihistamine, a corticosteroid, and an h2-antagonist

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
60MG/1.5ML (40MG/ML) SOLUTION;INTRAVENOUS Prescription

availability in other generic markets.

Click on the highlighted region to filter.